Physician profile
Timothy P Nuce
NPI 1376795674
$3,352.31
in general payments reported to CMS, 2019-2025
22 companies · $1,259 in 2025
The $1,259 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $18.60 · 2022: $441 · 2023: $803 · 2024: $830 · 2025: $1,259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,892.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,892.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $893.49 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $684.02 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Otsuka America Pharmaceutical, INC. | $260.46 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Boehringer Ingelheim Pharmaceuticals, INC. | $207.53 | 2022-2025 | Jardiance |
| Neurocrine Biosciences, INC. | $205.20 | 2022-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $151.89 | 2025 | Fanapt |
| Merck Sharp & Dohme LLC | $150.74 | 2022-2025 | Verquvo |
| Lilly USA, LLC | $139.82 | 2022-2025 | Mounjaro |
| Exact Sciences Corporation | $117.44 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $75.09 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $57.92 | 2022-2025 | Invega Sustenna, Invega |
| Novo Nordisk INC | $57.51 | 2023-2025 | Rybelsus, Ozempic, Tresiba |
| Amgen INC. | $53.66 | 2022-2025 | Repatha, Otezla |
| Teva Pharmaceuticals USA, INC. | $45.10 | 2023-2025 | Austedo Xr, Uzedy |
| Xeris Pharmaceuticals, INC. | $44.16 | 2023 | Gvoke Hypopen |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $41.72 | 2025 | Auvelity |
| Indivior INC. | $38.24 | 2023-2025 | Sublocade |
| Organon LLC | $31.71 | 2021-2022 | |
| Glaxosmithkline, LLC. | $31.56 | 2022-2023 | Arexvy |
| Pfizer INC. | $30.95 | 2023-2024 | |
| Actelion Pharmaceuticals US, INC. | $17.18 | 2023 | Opsumit, Uptravi |
| Lundbeck LLC | $16.92 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Nuce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.